Showing 751-760 of 1484 results for "".
- Oral IL-23 Receptor Antagonist Makes Waves in Tokyohttps://practicaldermatology.com/news/oral-il-23-receptor-antagonist-makes-waves-in-tokyo/2461716/Protagonist Therapeutics and Janssen Biotech, Inc.'s oral IL-23 receptor antagonist, JNJ-2113, performed well in Phase 1 and Pre-clinical Studies. JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstr
- Rare Skin Disease Update: Abeona's EB-101 Performs Well in a Phase 3 study of RDEBhttps://practicaldermatology.com/news/rare-skin-disease-update-abeonas-eb-101-performs-well-in-a-phase-3-study-of-rdeb/2461715/Abeona Therapeutics Inc.’s investigational EB-101 performed well in a Phase 3 study of recessive dystrophic epidermolysis bullosa (RDEB). Both co-primary endpoints were met, with the majority (81.4%) of randomized EB-101–treated wounds demonstrating ≥50% healing compared
- Cutera Update: Agreements Made With Pura Vida and RTW; New Board Members Appointedhttps://practicaldermatology.com/news/cutera-update-agreements-made-with-pura-vida-and-rtw-new-board-members-appointed/2461712/Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments LLC and RTW Investments LP, which collectively own more than 15% of the company’s outstanding shares. Pursuant to the agreements, Cutera will appo
- Resilia Pharmaceuticals Announces Return to Market of Neosalus Cream and Neosalus Lotionhttps://practicaldermatology.com/news/resilia-pharmaceuticals-announces-return-to-market-of-neosalus-cream-and-neosalus-lotion/2461697/Resilia Pharmaceuticals, Inc.’s Neosalus Cream and Neosalus Lotion are back. These products had not been available due to supply chain disruptions that occurred as a result of the COVID-19 public health crisis. Both Neosalus Lotion and Neosalus Cream use paten
- Cytrellis Taps New CTOhttps://practicaldermatology.com/news/cytrellis-taps-new-cto/2461695/Dr. Shiv Sabesan is Cytrellis Biosystems’ Chief Technology Officer. In his new role, Dr. Sabesan will lead the company's strategy as it continues to advance its proprietary ellacor Micro-Coring technology and expand indications. The technology was
- Dr. Suneel Chilukuri Named Hydrinity Accelerated Skin Science’s Chief Medical Advisorhttps://practicaldermatology.com/news/dr-suneel-chilukuri-named-hydrinity-accelerated-skin-sciences-chief-medical-advisor/2461692/Suneel Chilukuri, MD, is Hydrinity Accelerated Skin Science’s new Chief Medical Advisor. In this role, Dr. Chilukuri will chair the Hydrinity Accelerated Skin Science Medical Advisory Board. He will aid product development as well as develop and oversee all clinica
- Kerecis Introduces Fish-Skin Graft and Silicone Cover for Wound Treatmenthttps://practicaldermatology.com/news/kerecis-introduces-fish-skin-graft-and-silicone-cover-for-wound-treatment/2461686/Kerecis rolled out MariGen Shield, a treatment which integrates the company’s fish-skin graft with a silicone contact layer for treating chronic and complex wounds. The company also announced the results of a clinical study comparing the effectiveness of the Kerecis fish
- Cetaphil Teams Up with Makeup Artist Alexx Mayo for Lizzo's Upcoming Tourhttps://practicaldermatology.com/news/cetaphil-teams-up-with-makeup-artist-alexx-mayo-for-lizzos-upcoming-tour/2461684/Cetaphil cleansers and moisturizers will be an integral part of Lizzo’s skin prep and glam during her upcoming "Special" tour courtesy of makeup artist Alexx Mayo. The brand will enlist Alexx Mayo to create social content showcasing how he relies on
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operation
- EULAR News: Acelyrin's IL-17A Blocker Performs Well in PsAhttps://practicaldermatology.com/news/eular-news-acelyrins-il-17a-blocker-performs-well-in-psa/2461657/ACELYRIN, INC.’s IL-17A blocker izokibep demonstrated higher levels of response across psoriatic arthritis disease manifestations, according to 46-week data from a global Phase 2 trial of izokibep in psoriatic arthritis (PsA). Izokibep is a small pr